<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JIA</journal-id>
<journal-id journal-id-type="hwp">spjia</journal-id>
<journal-id journal-id-type="nlm-ta">J Int Assoc Provid AIDS Care</journal-id>
<journal-title>Journal of the International Association of Providers of AIDS Care (JIAPAC)</journal-title>
<issn pub-type="ppub">2325-9574</issn>
<issn pub-type="epub">2325-9582</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/2325957413488175</article-id>
<article-id pub-id-type="publisher-id">10.1177_2325957413488175</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Disseminated <italic>Mycobacterium sherrisii</italic> Infection in a US-Born, HIV-Infected Patient</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Lee</surname>
<given-names>Spencer M.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-2325957413488175">1</xref>
<xref ref-type="corresp" rid="corresp1-2325957413488175"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Myers</surname>
<given-names>Robert A.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-2325957413488175">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Singh</surname>
<given-names>Karnail</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-2325957413488175">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kansal</surname>
<given-names>Seema</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-2325957413488175">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-2325957413488175">
<label>1</label>Maricopa Medical Center, E Roosevelt St, Phoenix, AZ, USA</aff>
<author-notes>
<corresp id="corresp1-2325957413488175">Spencer M. Lee, Maricopa Medical Center, 2601 E Roosevelt St, Phoenix, AZ 85006, USA. Email: <email>spencermlee02@gmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2013</year>
</pub-date>
<volume>12</volume>
<issue>4</issue>
<fpage>245</fpage>
<lpage>246</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder></permissions>
<abstract>
<p>
<italic>Mycobacterium sherrisii</italic> was first described as a novel species in 2004 but recently has begun to be more formally recognized with the use of new sequencing techniques. There have only been about 10 cases reported internationally, and we report the first case of <italic>M sherrisii</italic> in the United States. The mycobacterium was isolated from acid-fast bacilli cultures of a specimen obtained from a bronchoalveolar lavage and blood in a newly diagnosed HIV-infected, US-born patient presenting with sepsis. The patient was started on streptomycin, ethambutol, azithromycin, and rifampin with an improved clinical course. This report indicates the clinical presentation along with the varying drug susceptibilities to the emerging <italic>M sherrisii</italic>.</p>
</abstract>
<kwd-group>
<kwd>mycobacterium</kwd>
<kwd>HIV</kwd>
<kwd>
<italic>sherrisii</italic>
</kwd>
<kwd>disseminated</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>July/August 2013</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="section1-2325957413488175">
<title>Introduction</title>
<p>
<italic>Mycobacterium sherrisii</italic> was first described and proposed as a novel group of atypical mycobacterium related to <italic>Mycobacterium simian</italic> in 2004 by Selvarangan et al.<sup><xref ref-type="bibr" rid="bibr1-2325957413488175">1</xref></sup> A more recent study further defined its phylogenetic position and proposed the formal recognition of <italic>M</italic> <italic>sherrisii</italic> with type strain 4773<sup>T </sup>(=ATCC BAA-832<sup>T</sup>=DSM 45441<sup>T</sup>).<sup><xref ref-type="bibr" rid="bibr2-2325957413488175">2</xref></sup> There have been 8 reported cases of this new strain, mostly occurring in Africa, and mainly in HIV-infected patients with a severely immunocompromised state. Only 1 case of pulmonary <italic>M sherrisii</italic> has been reported in a non-HIV-infected patient.<sup><xref ref-type="bibr" rid="bibr3-2325957413488175">3</xref></sup> Due to its recent recognition and close resemblance to <italic>M simiae</italic>, the clinical features of patients infected with disseminated <italic>M sherrisii</italic> are not yet known nor has the proper treatment with varied drug susceptibilities and clinical results been established.</p>
</sec>
<sec id="section2-2325957413488175">
<title>Case Report</title>
<p>A 48-year-old African American male born and raised in the United States was diagnosed with HIV and presumed Mycobacterium avium-intracellulare infection in February 2012. Initial absolute CD4 count was 2 cells/mm<sup>3</sup> with HIV RNA quantitative &gt;1million copies/mL. The patient started on clarithromycin, ethambutol, prednisone, and Bactrim DS with instructions to follow up at an HIV clinic for starting antiretroviral (ARV) medication. In May 2012, he was started on efavirenz (EFV), abacavir (ABC), and lamivudine (3TC). Three weeks later, he developed diarrhea, nausea, vomiting, and shortness of breath. His caseworker noticed increased confusion upon speaking with him on the telephone and recommended that he go to the emergency room. On physical examination, there were diminished lung sounds bilaterally with a regular tachycardia. He was disoriented to place but able to state name and date. No palpable lymph nodes or hepatosplenomegaly were evident. Neurodermatitis was present on bilateral arms, chest, and back. Over the next 24 hours, he became febrile, tachycardic, and hypotensive. Initial laboratory tests indicated acute renal insufficiency with an estimated glomerular filtration rate of 6, anion gap metabolic acidosis, and normocytic anemia. Computed tomography of the chest indicated right middle lobe and lower lobe opacities along with multiple enlarged portal, celiac, mesenteric, and retroperitoneal lymph nodes. Prior records were reviewed and bronchoalveolar lavage from previous hospitalization indicated an atypical mycobacterium most closely related to <italic>M simiae</italic>. The 16S ribosomal RNA sequencing was then performed to differentiate it from other atypical mycobacterium. Acid-fast bacilli blood cultures were also obtained and indicated <italic>M sherrisii</italic>. The patient underwent hemodialysis, which improved his mental status. Initial broad-spectrum antibiotics of vancomycin/cefepime were stopped, and he was placed on intramuscular streptomycin, intravenous azithromycin, oral ethambutol, and intravenous rifampin. The ARV medications were restarted (EFV, ABC, and 3TC). Repeat CD4 absolute count elevated to 40 cells/mm<sup>3</sup> and HIV RNA quantitative decreased to 153 copies/mL. Susceptibilities from both the blood and the sputum samples are listed. Streptomycin, ethambutol, azithromycin, and rifampin were started, and the patient clinically improved, so the medications were administered for 2 weeks, and then clarithromycin and ethambutol were orally continued.</p>
</sec>
<sec id="section3-2325957413488175">
<title>Discussion</title>
<p>Newer technology has resulted in a novel species of mycobacterium differentiated from the atypical mycobacterium group. With the gene sequencing technique, the identification of <italic>M sherrisii</italic> can be performed, but its clinical significance is yet to be determined. It is probable that many high-performance liquid chromatography methods have designated this new species as <italic>M simiae</italic> or labeled it as a member of the <italic>Simiae-Avium</italic> group. Further investigation will need to be done in regard to the clinical outcomes with varying drug combinations and approaches.</p>
</sec>
<sec id="section4-2325957413488175">
<title>Conclusion</title>
<p>The newly designated species of mycobacterium, <italic>M sherrisii</italic>, has been shown to cause infection in HIV-infected individuals. The few cases reported have mostly been from Africa<sup><xref ref-type="bibr" rid="bibr4-2325957413488175">4</xref><xref ref-type="bibr" rid="bibr5-2325957413488175"/>–<xref ref-type="bibr" rid="bibr6-2325957413488175">6</xref></sup> with 1 validated species in Thailand<sup><xref ref-type="bibr" rid="bibr7-2325957413488175">7</xref></sup> and most recently a reported case in Singapore.<sup><xref ref-type="bibr" rid="bibr8-2325957413488175">8</xref></sup> We report the first case of disseminated <italic>M sherrisii</italic> in the United States. The clinical features have varied from case to case, with some isolated pulmonary disease as well as disseminated disease. Our patient originally presented with respiratory symptoms that, after shortened therapy with clarithromycin, ethambutol, and prednisone due to noncompliance, further progressed into acute renal insufficiency and septic shock. The clinical response to treatment has varied across all the cases, along with drug susceptibilities described. Further characteristics of <italic>M sherrisii</italic> and its clinical significance will need to continue to be reported, as more cases are identified throughout the world.</p>
<table-wrap id="table1-2325957413488175" position="float">
<label>Table 1.</label>
<caption>
<p>Drug Susceptibilities.</p>
</caption>
<graphic alternate-form-of="table1-2325957413488175" xlink:href="10.1177_2325957413488175-table1.tif"/>
<table>
<thead>
<tr>
<th> </th>
<th>MIC, mcg/mL</th>
<th>MINT</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFB culture from BAL</td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> Amikacin</td>
<td>4</td>
<td>Intermediate</td>
</tr>
<tr>
<td> Ciprofloxacin</td>
<td>&gt;4</td>
<td>Resistant</td>
</tr>
<tr>
<td> Clarithromycin</td>
<td>≤4</td>
<td>Susceptible</td>
</tr>
<tr>
<td> Clofazimine</td>
<td>0.12</td>
<td>Susceptible</td>
</tr>
<tr>
<td> Ethambutol</td>
<td>4</td>
<td>Intermediate</td>
</tr>
<tr>
<td> Rifampin</td>
<td>&gt;8</td>
<td>Resistant</td>
</tr>
<tr>
<td> Rifabutin</td>
<td>&gt;0.5</td>
<td>Resistant</td>
</tr>
<tr>
<td> Streptomycin</td>
<td>≤2</td>
<td>Susceptible</td>
</tr>
<tr>
<td> Rifampin combo</td>
<td>8</td>
<td>Resistant</td>
</tr>
<tr>
<td> Etham combo</td>
<td>2</td>
<td>Susceptible</td>
</tr>
<tr>
<td>AFB blood culture</td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> Ciprofloxacin</td>
<td>&gt;4.0</td>
<td>Resistant</td>
</tr>
<tr>
<td> Clofazimine</td>
<td>&lt;0.06</td>
<td>Susceptible</td>
</tr>
<tr>
<td> Rifabutin</td>
<td>&gt;0.5</td>
<td>Resistant</td>
</tr>
<tr>
<td> Rifampin</td>
<td>8</td>
<td>Resistant</td>
</tr>
<tr>
<td> Ethambutol</td>
<td>4</td>
<td>Intermediate</td>
</tr>
<tr>
<td> Streptomycin</td>
<td>4</td>
<td>Intermediate</td>
</tr>
<tr>
<td> Amikacin</td>
<td>8</td>
<td>Resistant</td>
</tr>
<tr>
<td> Clarithromycin</td>
<td>≤4.0</td>
<td>Susceptible</td>
</tr>
<tr>
<td> Rifampin combo</td>
<td>4</td>
<td>Intermediate</td>
</tr>
<tr>
<td> Ethambutol combo</td>
<td>2</td>
<td>Susceptible</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-2325957413488175">
<p>Abbreviations: AFB, acid-fast bacilli; BAL, bronchoalveolar lavage; MIC, minimum inhibitory concentration; MINT, minimum inhibitory concentration interpretation.</p>
<p>Source: National Jewish Health, Mycobacteriology, Denver, CO.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-2325957413488175">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-2325957413488175">
<label>Funding</label>
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-2325957413488175">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selvarangan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>WK</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>TT</given-names>
</name>
<etal/>
</person-group>. <article-title>Characterization of a novel group of mycobacteria and proposal of mycobacterium sherrisii sp nov</article-title>. <source>J Clin Microbiol</source>. <year>2004</year>;<volume>42</volume>(<issue>1</issue>):<fpage>52</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr2-2325957413488175">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Ingen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tortoli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Selvarangan</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Mycobacterium sherrisii sp nov., a slow-growing non-chromogenic species</article-title>. <source>Int J Syst Evol</source>. <year>2011</year>;<volume>61</volume>(<issue>pt 6</issue>):<fpage>1293</fpage>–<lpage>1298</lpage>.</citation>
</ref>
<ref id="bibr3-2325957413488175">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tortoli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mariottini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mazzarelli</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Mycobacterium sherrisii isolation from a patient with pulmonary disease</article-title>. <source>Diag Microbiol Inf Dis</source>. <year>2007</year>;<volume>57</volume>(<issue>2</issue>):<fpage>221</fpage>–<lpage>223</lpage>.</citation>
</ref>
<ref id="bibr4-2325957413488175">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tortoli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Galli</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Andebirhan</surname>
<given-names>SB</given-names>
</name>
<etal/>
</person-group>. <article-title>The first case of Mycobacterium sherrisii disseminated infection in a child with AIDS</article-title>. <source>AIDS</source>. <year>2007</year>;<volume>21</volume>(<issue>11</issue>):<fpage>1496</fpage>–<lpage>1498</lpage>.</citation>
</ref>
<ref id="bibr5-2325957413488175">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crump</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>van Ingen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Morrissey</surname>
<given-names>AB</given-names>
</name>
<etal/>
</person-group>. <article-title>Invasive disease caused by nontuberculous mycobacteria, Tanzania</article-title>. <source>Emerg Inf Dis.</source> <year>2009</year>;<volume>15</volume>(<issue>1</issue>):<fpage>53</fpage>–<lpage>55</lpage>.</citation>
</ref>
<ref id="bibr6-2325957413488175">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loulergue</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lamontagne</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Vincent</surname>
<given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>Mycobacterium sherrisii: new opportunistic agent in HIV infection?</article-title> <source>AIDS</source>. <year>2007</year>;<volume>21</volume>(<issue>7</issue>):<fpage>893</fpage>–<lpage>894</lpage>.</citation>
</ref>
<ref id="bibr7-2325957413488175">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ballard</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Turenne</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Wolfe</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Reller</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Kabani</surname>
<given-names>A.</given-names>
</name>
</person-group> <article-title>Molecular characterization of nontuberculous mycobacteria isolated from human cases of disseminated disease in the USA, Thailand, Malawi, and Tanzania</article-title>. <source>J Gen Appl Microbiol</source>. <year>2007</year>;<volume>53</volume>(<issue>2</issue>):<fpage>153</fpage>–<lpage>157</lpage>.</citation>
</ref>
<ref id="bibr8-2325957413488175">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ho</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Balm</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Huggan</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Immune reconstitution inflammatory syndrome associated with disseminated Mycobacterium sherrisii infection</article-title>. <source>Int Journal STD AIDS</source>. <year>2012</year>;<volume>23</volume>(<issue>5</issue>):<fpage>369</fpage>–<lpage>370</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>